Emergent BioSolutions | EBS - Marktkapitalisierung

Aktienkurs
8.81
Täglich Wechseln
0.19 2.20%
Monatlich
10.13%
Jährlich
94.05%
Q2 Prognose
8.43




Marktkapitalisierung Veränderung Datum
Acadia Pharmaceuticals USD 4.52B 919M 2025-12
Akebia Therapeutics USD 427M 297M 2025-12
ALKERMES USD 4.62B 333M 2025-12
Alnylam Pharmaceuticals USD 52.54B 7.24B 2025-12
Amarin USD 290M 51M 2025-12
ANI Pharmaceuticals USD 1.77B 269M 2025-12
BioMarin Pharmaceutical USD 11.42B 1.02B 2025-12
Coherus Biosciences USD 172M 19M 2025-12
Emergent BioSolutions USD 125M 51M 2023-12
Exelixis USD 11.75B 959M 2025-12
Glaxosmithkline GBP 99.93B 13.05B 2025-12
Heron Therapeutics USD 238M 7M 2025-12
Ionis Pharmaceuticals USD 12.81B 2.39B 2025-12
Lexicon Pharmaceuticals USD 418M 73M 2025-12
Lonza CHF 39.68B 980.61M 2025-06
Merck USD 261.26B 51.62B 2025-12
Myriad Genetics USD 575M 98M 2025-12
Nektar Therapeutics USD 14.34B 13.48B 2026-04
Neurocrine Biosciences USD 14.14B 218M 2025-12
Pacira USD 1.06B 94M 2025-12
Pfizer USD 141.57B 6.48B 2025-12
PTC Therapeutics USD 6.1B 1.22B 2025-12
Sanofi EUR 100.88B 4.46B 2025-12
Sarepta Therapeutics USD 2.26B 238M 2025-12
United Therapeutics USD 20.98B 2.02B 2025-12
Vanda Pharmaceuticals USD 279M 6M 2024-12